

C. David Adair, M.D.

Over the past 10 years, Dr. Adair has led or participated in several investments of both biopharmaceutical and medical device companies as a part of the Angel investment group.

Investments have been placed from “Angel” source funding to late phase placements in all facets of biotechnology. The portfolio of investments includes; 1) Veran Medical, of St. Louis, MO, an industry leading oncologic solution for navigation in the pulmonary space, 2) Nx Thera Medical, Maple Grove, MN, currently marketing the Rezum system for benign prostatic hypertrophy in the EU and anticipates FDA clearance in the very near future, 3) Therakine, Inc., Berlin, Germany, specializing in GRAS incipient, which is utilized for drug delivery allowing timed payload deployment of small peptides, antibodies, and other therapeutics resulting in dosing advantages thereby expanding from daily administration to every 6 to 12 months. This uses technology originally developed in the Charite’, Berlin, Germany. 4) Aegea Medical, Redwood City, CA, is the latest investment, which uses the technology from Nx Thera for endometrial ablation. They have completed their trial enrollment and will complete the study in 2016.

The Angel investment group has had several successful exits to commercial partners through either license or outright acquisitions e.g., 5) Addrenex Pharmaceuticals, Research Triangle Park, NC to Scielle Pharma (SCRX: NASDAQ), a Shionogi Company, Osaka, Japan, an acquisition of all assets for over \$30mm U.S. in November 2009. The lead product was Kapvay for non-stimulation approach for ADHD. 6) Neuronex Inc., Morrisville, NC, merger with Acorda Therapeutics (ACOR: NASDAQ), Ardsley, NY for \$133 mm in February, 2012. The one asset acquisition was for intranasal valium, Plumiaz, for cluster seizures that was granted Orphan drug status by the FDA. 7) Aerial Bio Pharma, of Morrisville, NC successfully out-licensed ADX-NO5, a novel compound for excessive daytime sleepiness associated with narcolepsy to Jazz Pharmaceuticals (JAZZ:NASDAQ) for over 400mm. Our most recent participation was for an investment to complete Series B and license option for 8) Advanced Catheter Therapy of Chattanooga, TN to Toray Medical, Tokyo, Japan.

As well as assisting with study design, site selection, and active physician supporter worldwide, Dave has served on all of the portfolio boards as a director or observer. He is also the Chairman and chief science officer of Glenveigh Medical, Chattanooga, TN.

Glenveigh has had several successful exits including two medical devices to Clinical Innovations, Salt Lake City, Utah, and Protherics, Inc. (PTIL:FTSE) . Glenveigh recently formed a joint venture with Velo Bio of Morrisville, NC. This resulted in an out-license option to AMAG Pharmaceuticals, Waltham, MA (AMAG:NASDAQ).

He is founder and general manager of Solas Bioventures, LLC, which was established this year and successfully closed on over 10 mm dollars under his management.

He is a co-founder of Regional Obstetrics Consultants in Chattanooga, TN where he currently serves as CEO. He is a Professor and Vice Chairman of Obstetrics and Gynecology at the University Of Tennessee College Of Medicine. He holds the same adjunctive rank at Chattanooga State Community College, Department of Ultrasound and an adjunctive faculty member of the Biological Sciences department at The University of Tennessee Chattanooga. He has published more than seventy articles, numerous book chapters. He has received multiple teaching awards and has been PI or Co-PI on over \$30 million dollars of grants, contracts, and awards.

Dave attended Morehead State University where he was inducted in MSU Hall of Fame in 2009. He received his Medical Doctorate from Marshall University and completed a Residency in Obstetrics and Gynecology at the University of Florida Health

Science Center. He further pursued fellowship in Maternal Fetal Medicine at Wake Forest University.

Dave also had the opportunity and good fortune to have external training at The National Maternity Hospital, Dublin, Ireland and Mass General Hospital of the Harvard Medical School Section on Nephrology as well as the same at Henry Ford Hospital.

He has lectured extensively all over the world on Postpartum Hemorrhage, Preeclampsia, Prematurity, and Infections affecting pregnancy.

He is the personal holder of several patents and has been instrumental in bringing two medical devices to market in the field of obstetrics, the Ebb and Jetty.

Dave was the 2015 SEMDA Spotlight award recipient.

Contact information:

adair@rocob.com

423-664-4460 practice office